Barorezeptorakivierungstherapie bei therapierefraktärer Hypertonie

• Verfasst von: Koziolek, Michael Johann [VerfasserIn]
• Verfasst von: Krämer, Bernhard [VerfasserIn]
• Titel: Barorezeptorakivierungstherapie bei therapierefraktärer Hypertonie
• Titelzusatz: Indikation und Patientenselektion : Empfehlungen der BAT-Konsensusgruppe 2017
• Paralleltitel: Baroreceptor activation therapy for therapy-resistant hypertension
• Paralleltitelzusatz: indications and patient selection : recommendations of the BAT consensus group 2017
• Verf.angabe: M. Koziolek, J. Beige, M. Wallbach, D. Zenker, G. Henning, M. Halbach, N. Mader, F. Mahfoud, G. Schlieper, V. Schwenger, M. Hausberg, J. Börgel, M. Lodde, M. van der Giet, J. Müller-Ehmsen, J. Passauer, S. Parmentier, S. Lüders, B.K. Krämer, S. Büttner, F. Limbourg, J. Jordan, O. Vonend, H.-G. Predel, H. Reuter
• E-Jahr: 2017
• Jahr: 23. August 2017
• Umfang: 10 S.
• Fussnoten: Gesehen am 13.08.2018
• Titel Quelle: Enthalten in: Der Internist
• Ort Quelle: Berlin : Springer, 1996
• Jahr Quelle: 2017
• Band/Heft Quelle: 58(2017), 10, Seite 1114-1123
• ISSN Quelle: 1432-1289
• DOI: doi:10.1007/s00108-017-0308-y
• Datenträger: Online-Ressource
• Sprache: ger
• K10plus-PPN: 1578530202

Abstract

Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.